Lauren Wolchok
Family Medicine · Pasadena, CANPI 1033556022
Payments from drug & device makers
Across 196 payments — averaging $24.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- Viiv Healthcare Company$1K
- Merck$347
- AbbVie$182
- Indivior Inc.$177
- Alkermes, Inc.$147
- plus $504 from 8 others
What the payments were for
- Food & beverage$4,759100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 82 | $2,027 |
| Viiv Healthcare Company | 55 | $1,375 |
| Merck | 15 | $347 |
| AbbVie | 9 | $182 |
| Indivior Inc. | 6 | $177 |
| Alkermes, Inc. | 7 | $147 |
| Theratechnologies Inc. | 4 | $126 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $109 |
| Napo Pharmaceuticals Inc | 5 | $106 |
| Johnson & Johnson | 4 | $87 |
| Janssen Scientific Affairs, LLC | 1 | $25 |
| Pfizer | 1 | $20 |
| Vyera Pharmaceuticals, LLC | 1 | $17 |
| EMD Serono, Inc. | 1 | $14 |
How this compares
$4,759 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 281 | $1,105,426 |
| DovatoDolutegravir Sodium/Lamivudine | 126 | $365,856 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 49 | $251,314 |
| JulucaDolutegravir/Rilpivirine | 69 | $231,724 |
| CabenuvaCabotegravir/Rilpivirine | 22 | $145,511 |
| TivicayDolutegravir Sodium | 31 | $66,757 |
| PifeltroDoravirine | 12 | $18,582 |
| RybelsusSemaglutide | 14 | $16,782 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $14,492 |
| FarxigaDapagliflozin Propanediol | 26 | $13,836 |
| TrulancePlecanatide | 12 | $6,560 |
| EntrestoSacubitril/Valsartan | 11 | $6,200 |
| Varenicline Tartrate | 16 | $2,867 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 78 | $2,436 |
| Icosapent Ethyl | 18 | $2,056 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $2,027 | $1,105,426281 claims |
| Viiv Healthcare CompanyDovato, Juluca, Cabenuva, Tivicay | $1,375 | $809,849248 claims |
| MerckPifeltro | $347 | $18,58212 claims |
| AbbVieSynthroid | $182 | $1,09816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Pasadena
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.